|
Key figures for 2009 |
XLS | ||||
|
|
|
|
|
|
|
|
€ million |
Pharma- |
Chemicals |
Corporate |
Total |
Change |
|
Total revenues |
5,812 |
1,935 |
0 |
7,747 |
2.1 |
|
Gross margin |
4,805 |
913 |
0 |
5,718 |
0.6 |
|
Research and development |
1,203 |
142 |
– |
1,345 |
8.9 |
|
Operating result |
403 |
324 |
–78 |
649 |
–43 |
|
Exceptional items |
–40 |
12 |
– |
–28 |
– |
|
Earnings before interest and tax (EBIT) |
363 |
336 |
–78 |
621 |
–15 |
|
EBIT before depreciation and amortization (EBITDA) |
1,221 |
479 |
–75 |
1,625 |
–17 |
|
Return on sales in % (ROS: operating result/total revenues) |
6.9 |
16.8 |
– |
8.4 |
|
|
Free cash flow |
913 |
410 |
–511 |
812 |
85 |
|
Underlying free cash flow |
916 |
432 |
–496 |
852 |
42 |
|
Underlying free cash flow on revenues (FCR) in % |
15.8 |
22.3 |
– |
11.0 |
|
Total revenues by business sector*€ million  |
Operating result by business sector€ million  |